{"commentary":{"count":297,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":128,"youtube":82,"podcast":82,"x_video":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03036098\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate901","nct_id":"NCT03036098","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate901-nct03036098. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CheckMate901","arms":[{"description":null,"label":"Arm A: Investigational immunotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B: Standard of care chemotherapy","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Arm C: Investigational immunotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Arm D: Standard of care chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Ono Pharmaceutical Co., Ltd."],"completion_date":{"date":"2026-05-15","type":"ESTIMATED"},"conditions":["Urothelial Cancer"],"enrollment":{"count":1314,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","type":"BIOLOGICAL"},{"name":"Ipilimumab","type":"BIOLOGICAL"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"}],"last_update":"2026-03-06","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-08-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study","timeFrame":"From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)"},{"measure":"Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study","timeFrame":"From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)"},{"measure":"Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study","timeFrame":"From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)"},{"measure":"Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study","timeFrame":"From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)"}],"references":[{"citation":"Tomita Y, Ye DW, Fujii A, Takeuchi N. Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial. Urol Oncol. 2025 Dec;43(12):696.e9-696.e16. doi: 10.1016/j.urolonc.2025.08.022. Epub 2025 Sep 26.","pmid":"41015742","type":"DERIVED"},{"citation":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Urun Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023 Nov 9;389(19):1778-1789. doi: 10.1056/NEJMoa2309863. Epub 2023 Oct 22.","pmid":"37870949","type":"DERIVED"}],"start_date":{"date":"2017-03-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","url":"https://clinicaltrials.gov/study/NCT03036098"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate901-nct03036098"}